Regenxbio (RGNX) closed at $7.16 on November 20, 2026, down 0.3% from the previous close, on volume of 990,943 shares (30-day average 1,183,198).
Data as of November 20, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 19, 2026. See the largest for 5, 30, 60 and 90 days
Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and CVS Health (CVS)
TipRanks (Fri, 20-Nov 10:20 AM ET)
Stocks to Watch for Wednesday: TJX, TTWO, TGT & more
Seeking Alpha News (Wed, 18-Nov 10:10 AM ET)
Capricor, Regenxbio among gainers as White House pulls Trump’s FDA pick
Seeking Alpha News (Wed, 18-Nov 9:06 AM ET)
REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
PRNewswire (Thu, 5-Nov 7:05 AM ET)
REGENXBIO to Participate in Stifel 2026 Healthcare Conference
PRNewswire (Tue, 3-Nov 7:05 AM ET)
PRNewswire (Thu, 29-Oct 7:05 AM ET)
Market Chameleon (Tue, 13-Oct 7:16 AM ET)
PRNewswire (Mon, 12-Oct 7:05 AM ET)
PRNewswire (Thu, 24-Sep 7:18 PM ET)
REGENXBIO to Participate in Upcoming Investor Conferences
PRNewswire (Tue, 8-Sep 7:05 AM ET)
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Regenxbio trades on the NASDAQ stock market under the symbol RGNX.
As of November 20, 2026, RGNX stock price declined to $7.16 with 990,943 million shares trading.
RGNX has a beta of 2.47, meaning it tends to be more sensitive to market movements. RGNX has a correlation of 0.09 to the broad based SPY ETF.
RGNX has a market cap of $472.65 million. This is considered a Small Cap stock.
Last quarter Regenxbio reported $9 million in Revenue and -$.62 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.69.
In the last 3 years, RGNX traded as high as $28.80 and as low as $5.04.
The top ETF exchange traded funds that RGNX belongs to (by Net Assets): XBI, IWM, VTI, VXF, FESM.
RGNX has underperformed the market in the last year with a return of -34.5%, while the SPY ETF gained +5.2%. In the last 3 month period, RGNX fell short of the market, returning -40.4%, while SPY returned -10.1%. However, in the most recent 2 weeks RGNX has outperformed the stock market by returning -3.0%, while SPY returned -5.9%.
RGNX support price is $6.82 and resistance is $7.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RGNX shares will trade within this expected range on the day.